News

NIAID Anticipates Funding Host-Based Approaches to Antimicrobial Resistance BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – August 15, 2015) BioAegis Therapeutics announces that it has met with representatives from The National Institute of Allergy and Infectious Diseases (NIAID) and The Biomedical Advanced Research Development Agency (BARDA) to discuss plasma gelsolin’s role in in combatting antibiotic …

August 15, 2015: BioAegis Therapeutics Presents to NIAID and BARDA Regarding Plasma Gelsolin and Its Role in Combatting Antimicrobial Resistance Read More »

Despite rigorous, contemporary methodology, pathogens are not identified in the majority of CAP cases. In addition, viruses play a role greater than previously recognized and were detected almost twice as frequently as bacteria. This study indicates a need for a host-based approach which does not depend on a specific pathogen, such as BioAegis’ plasma gelsolin …

July, 2015: New England Journal of Medicine Publication, “Community-Acquired Pneumonia Requiring Hospitalization among US Adults” Indicates Need for Host-Based Therapies Read More »

Dr. Lester Kobzik, Professor of Medicine, Harvard T.H. Chan School of Public Health Publishes: Plasma gelsolin improves lung host defense against pneumonia by enhancing macrophage NOS3 function. This major plasma gelsolin advancement was published in May in Journal of American Physiology—Lung, Cellular and Molecular Physiology. Read article here.

Company Enters into Collaborative Research Agreement with NIAID and Company to Run Phase 2a/b Trials in EU BioAegis Therapeutics Inc., a privately held biotechnology company commercializing plasma gelsolin (pGSN), an endogenous human protein that simultaneously modulates inflammation and boosts immune function announced that its recently closed convertible note round was oversubscribed by investors. Read article …

April 15, 2015: BioAegis Therapeutics Completes Initial $8 Million Convertible Note: Round Oversubscribed Read More »

Data to Further Inform Design of Phase 2 Studies BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) December, 2014 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has established collaborations with Vanderbilt and Northwestern Universities to analyze plasma gelsolin levels in a well-adjudicated population of …

December, 2014: BioAegis Establishes Collaboration with Vanderbilt and Northwestern to Measure Plasma Gelsolin Levels in Community-Acquired Pneumonia Patients Read More »

Recombinant human plasma gelsolin has demonstrated efficacy against both gram positive and gram negative bacteria. This adds to our broad geographic coverage, including a patent granted last year in China. BioAegis is pursuing worldwide patent filings for infectious disease.

Initial Funding Effort to Advance Recombinant Plasma Gelsolin Therapy into Human Trials BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that it has closed its final tranche of an $8MM convertible note round. These funds will be used to advance its clinical program into human clinical trials in severe …

December 3, 2014: BioAegis Therapeutics Closes Successful $8MM Convertible Note Round Read More »

Patent Covers Therapeutic Uses of Plasma Gelsolin in Renal Failure BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – December 3, 2014) BioAegis Therapeutics announces that its portfolio of patents has been expanded with the granting of a second European Patent for plasma gelsolin. Claims in this patent are directed to the treatment of renal failure.

Initial Effort to Elucidate the Role of Plasma Gelsolin in Human Diseases with Significant Inflammatory and Infectious Disease Complications BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics has announced that it has entered into a research collaboration with the National Institute of Allergy and Infectious Diseases. NIAID, which is one …

November 10, 2014: BioAegis and the National Institute of Allergy and Infectious Diseases (NIAID) Enter into Research Collaboration Read More »

Company To Sponsor Phase 2 Trials in Community-Acquired Pneumonia in Europe BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 10, 2014) BioAegis Therapeutics reports that its clinical program was well-­received by two EU regulatory authorities, the MHRA in the United Kingdom and the MPA in Sweden. After completion of required preparatory work the company …

November 10, 2014: BioAegis Therapeutics Seeks Advice from MHRA and MPA in Anticipation of European Phase 2 Clinical Studies Read More »